	US 12,257,252 B2
	Compositions and methods for increasing tetrahydrobiopterin plasma exposure
Neil Smith, Cary, NC (US); and Jonathan Reis, Brookline, MA (US)
Assigned to PTC Therapeutics MP, Inc., Warren, NJ (US)
Appl. No. 17/059,632
Filed by PTC Therapeutics MP, Inc., South Plainfield, NJ (US)
PCT Filed May 30, 2019, PCT No. PCT/US2019/034515 § 371(c)(1), (2) Date Nov. 30, 2020, PCT Pub. No. WO2019/232126, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/822,365, filed on Mar. 22, 2019.
Claims priority of provisional application 62/771,397, filed on Nov. 26, 2018.
Claims priority of provisional application 62/677,926, filed on May 30, 2018.
Claims priority of application No. 2019/37662 (GC), filed on May 28, 2019.
Prior Publication US 2021/0161901 A1, Jun. 3, 2021
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0065 (2013.01)]

13 Claims

1. A method of therapeutic treatment of a BH4-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of sepiapterin, or a pharmaceutically acceptable salt thereof, with food,

wherein the BH4-related disorder is a BH4 deficiency, high plasma phenylalanine, or phenylketonuria.